ARTICLE

Volume 10,Issue 7

All Issues
Submit to JCNR
Cite this article
1
Citations
2
Views
17 February 2025
Clinical Significance of Alpha-Fetoprotein Levels in Artificial Liver Therapy for Liver Failure
Xiju Guo ,  Weibo Guo ,  Luyao Wang ,  Yongping Wang ,  Mingmei Liao ,  Yingshan Liao
Show Less
1 Department of Gastroenterology, Baoshan People’s Hospital of Yunnan Province, Baoshan 678000, Yunnan Province, China,
2 Department of Gastroenterology, Second Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan Province, China,
JCNR 2025 , 9(1), 305–313; https://doi.org/10.26689/jcnr.v9i1.9518
© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
HTML
Abstract

Objective: To investigate the predictive value and clinical significance of alpha-fetoprotein (AFP) levels in the prognosis of patients with liver failure treated with artificial liver plasma exchange (PE). Methods: A retrospective analysis was conducted on the clinical data of 96 liver failure patients. All patients underwent artificial liver plasma exchange therapy in addition to internal medicine treatments. Based on AFP test results, patients were divided into a low-AFP group (AFP < 100 ng/mL, n = 32), a medium-AFP group (100 ≤ AFP < 200 ng/mL, n = 32), and a high-AFP group (AFP ≥ 200 ng/mL, n = 32). Serum AFP levels were measured before artificial liver therapy (2nd day of admission), and on the 1st, 10th, and 20th day after therapy, as well as the final day (before discharge or end of life), to observe their variations. Results: Among the 96 patients, there were 4 cases (4.2%) of acute liver failure (ALF), 7 cases (7.3%) of subacute liver failure (SALF), 57 cases (59.4%) of acute-on-chronic liver failure (ACLF), and 28 cases (29.2%) of chronic liver failure (CLF), with an overall survival rate of 82.3% (79/96). The survival rate in the AFP < 100 ng/mL group was lower than in the other two groups, and the survival rate increased progressively with rising AFP levels (P < 0.05). Conclusion: Serum AFP levels are closely related to the efficacy of artificial liver plasma exchange therapy in liver failure patients. Monitoring the dynamic changes in AFP levels can help assess disease progression.

References
Chinese Society of Infectious Diseases, Liver Failure, and Artificial Liver Group, 2016, Guidelines for Non-Bioartificial Liver Therapy for Liver Failure (2016 Edition). Chinese Journal of Clinical Infectious Diseases, 9(2): 97–103.
Chinese Society of Infectious Diseases, Liver Failure and Artificial Liver Group; Chinese Society of Hepatology, Severe Liver Disease and Artificial Liver Group, 2018, Guidelines for Diagnosis and Treatment of Liver Failure (2018 Edition). Modern Medicine and Health, 34(24): 3897–3904.
Neuberger J, 2005, Prediction of Survival for Patients with Fulminant Hepatic Failure. Hepatology, 41(1): 19–22. https://doi.org/10.1002/hep.20562
Chen JJ, Huang JR, Yang Q, et al., 2016, Plasma Exchange-centered Artificial Liver Support System in Hepatitis B Virus-related Acute-on-Chronic Liver Failure: A Nationwide Prospective Multicenter Study in China. Hepatobiliary Pancreat Dis Int, 15(3): 275–281. https://doi.org/10.1016/s1499-3872(16)60084-x
Huang M, Lu Y, Chen Y, 2013, Analysis and Model Construction of Short-Term Prognostic Factors for Hepatitis B Liver Failure. Guangdong Medical Journal, 34(16): 2543–2546.
Qin S, Tang S, Wang X, et al., 2020, The Value of Serum Alpha-Fetoprotein in Prognostic Evaluation of Hepatitis B-Related Acute-on-Chronic Liver Failure Treated with Artificial Liver. Chinese Journal of Hepatology, 28(1): 69–72.
Sen S, Williams R, Jalan R, 2002, The Pathophysiological Basis of Acute-on-Chronic Liver Failure. Liver, 22 Suppl 2: 5–13. http://doi.org/10.1034/j.1600-0676.2002.00001.x
Kamath PS, Kim WR; Advanced Liver Disease Study Group, 2007, The Model for End-stage Liver Disease (MELD). Hepatology, 45(3): 797–805. http://doi.org/10.1002/hep.21563
Aguirre-Valadez J, Torre A, Vilatobá M, et al., 2014, Indicaciones de Trasplante Hepático [Indications for Liver Transplant]. Rev Invest Clin, 66(6): 534–546.
Wang X, Shen C, Yang J, et al., 2018, Alpha-Fetoprotein as a Predictive Marker for Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Can J Gastroenterol Hepatol, 2018: 1232785. http://doi.org/10.1155/2018/1232785
Yang F, Peng L, Liu Y, et al., 2017, Advances in the Diagnosis and Treatment of Liver Failure in 2016. Chinese Journal of Hepatology, 25(2): 94–99.
Nevens F, Laleman W, 2012, Artificial Liver Support Devices as Treatment Option for Liver Failure. Best Pract Res Clin Gastroenterol, 26(1): 17–26. http://doi.org/10.1016/j.bpg.2012.01.002
Pless G, 2007, Artificial and Bioartificial Liver Support. Organogenesis, 3(1): 20–24. http://doi.org/10.4161/org.3.1.3635
García Martínez JJ, Bendjelid K, 2018, Artificial Liver Support Systems: What is New Over the Last Decade? Ann Intensive Care, 8(1): 109. http://doi.org/10.1186/s13613-018-0453-z
Selden C, Bundy J, Erro E, et al., 2017, A Clinical-scale BioArtificial Liver, Developed for GMP, Improved Clinical Parameters of Liver Function in Porcine Liver Failure. Sci Rep, 7(1): 14518. http://doi.org/10.1038/s41598-017-15021-4
Xia Q, Dai X, Huang J, et al., 2014, A Single-center Experience of Non-bioartificial Liver Support Systems Among Chinese Patients with Liver Failure. Int J Artif Organs, 37(6): 442–454. http://doi.org/10.5301/ijao.5000341
Wang X, Huang J, 2018, Advances in the Application of Artificial Liver in Liver Failure. Journal of Clinical Hepatobiliary Diseases, 34(9): 1847–1853.
Share
Back to top
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept